Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 study evaluating the efficacy and safety of controlled-release arbaclofen placarbil (XP19986) for gastroesophage…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Arbaclofen placarbil (XP19986) (arbaclofen placarbil)

Snippet

Sponsor: Indivior Inc. | Conditions: GERD | Phase 2 | Status: COMPLETED